Novartis stock trades near recent high as Kisunla approval and solid growth reshape outlook

Novartis AG (ISIN CH0012005267) stock is trading near the upper end of its recent range after the Swiss healthcare group reported mid single-digit sales growth and a double-digit increase in core operating income for the first quarter of 2026 according to its earnings documentation published in April 2026. The company also underpinned its profile as a large-cap global pharma name listed on SIX Swiss Exchange with steady margin expansion and a growing contribution from newer medicines.

Core operating income up around 13 percent

According to the Q1 2026 results presentation published by Novartis investor relations, net sales reached roughly $12.3 billion in the first quarter of 2026, compared with about $11.8 billion in the same period of 2025. This corresponds to year-on-year growth of around 4 percent on a reported basis, driven mainly by key growth brands in immunology, oncology, and cardiovascular medicine.

On the earnings side, core operating income for Q1 2026 came in at close to $4.0 billion, up about 13 percent versus approximately $3.5 billion in Q1 2025, reflecting positive operating leverage and a favorable product mix. Management highlighted in its April 2026 materials that the core operating income margin expanded by roughly 2 percentage points year on year, illustrating that profitability is improving more quickly than headline revenue.

Revenue above $50 billion in 2025

For the full year 2025, Novartis reported net sales of slightly above $52 billion according to its annual results documentation available via company investor materials. This represented mid single-digit growth from roughly $50 billion in 2024, supported by expanding demand for newer medicines and a phased impact from older product patent expirations. Core net income for 2025 was reported at around $16 billion, compared with about $14.6 billion in 2024, implying growth in the high single-digit to low double-digit percentage range and demonstrating resilient earnings power.

Novartis also returned capital to shareholders, stating in its 2025 materials that it paid a dividend of CHF 3.40 per share for the 2025 financial year, up from CHF 3.30 per share for 2024. That increase of CHF 0.10 per share illustrates the companys policy of gradual annual dividend growth. For income-oriented investors, the combination of a rising Swiss franc dividend and stable large-cap profile is an important element of the investment case, alongside the development pipeline.

Alzheimers therapy Kisunla gains US approval

A key product development for Novartis stock in 2026 is the US approval of the Alzheimers disease therapy Kisunla (donanemab-azbt). According to a detailed product announcement and background information published by the company and health authorities in mid 2026, Kisunla received approval for the treatment of adults with early symptomatic Alzheimers disease with confirmed amyloid pathology. The product is administered as an intravenous infusion, adding to the landscape of disease-modifying Alzheimers treatments.

In its materials, Novartis indicated that clinical trial data showed that Kisunla slowed cognitive and functional decline in patients with early symptomatic Alzheimers compared with placebo over an eighteen month treatment period. While the company has not yet quantified full-year revenue expectations for Kisunla, the therapy addresses a large and growing market, and even a modest initial uptake could translate into hundreds of millions of dollars of annual sales over the medium term. For investors, the product reinforces the strategic emphasis on high-impact innovative medicines in neurology and complements existing strengths in oncology and immunology.

Analysts covering large pharmaceutical groups have noted that the market for Alzheimers treatments is competitive, with other monoclonal antibody approaches already on the market. However, they also point out that multiple effective options are likely to be needed given the scale of the disease burden. For Novartis, the opportunity is not only direct revenue from Kisunla but also the signaling effect that its research and development platform can deliver late-stage assets in complex neurological diseases.

Entresto and Cosentyx remain major growth drivers

Besides the new Alzheimers therapy, established cardiovascular and immunology drugs continue to support the Novartis income statement. According to the 2025 annual results materials hosted on the companys investor pages, the heart-failure medicine Entresto generated net sales of around $7.0 billion in 2025, up from about $6.2 billion in 2024. That corresponds to year-on-year growth of roughly 13 percent, underlining the medicines ongoing penetration in guideline-directed therapy for chronic heart failure.

The immunology drug Cosentyx, used in psoriasis and several inflammatory joint conditions, delivered 2025 net sales of approximately $6.0 billion, compared with roughly $5.6 billion in 2024. This implies growth of about 7 percent over the prior year, driven by higher volumes across several indications, despite increasing competition in certain autoimmune markets. Together, Entresto and Cosentyx accounted for more than $13 billion of net sales in 2025, representing a significant share of group revenue and illustrating the concentration of earnings in a handful of blockbuster products.

From an investor perspective, the strength of these brands provides both an earnings cushion and a source of free cash flow that can support pipeline investment, bolt-on transactions, and shareholder returns. At the same time, the reliance on a limited number of very large products highlights the importance of managing patent expiry timelines and defending market share against newer entrants. The approval and future uptake of Kisunla and other pipeline assets can therefore play an important role in diversifying the revenue base over the coming years.

Kisunla shapes perception of innovative medicines strategy

Strategically, Novartis has spent recent years simplifying its portfolio and focusing on innovative prescription medicines, including the spin-off of its Sandoz generics unit. The emphasis in investor communication has been on building a portfolio concentrated around a dozen or so major brands with multibillion-dollar potential each, complemented by a steady stream of mid-size launches. Kisunla fits this pattern by targeting a high unmet medical need with the potential for meaningful long-term sales if the clinical benefits observed in trials are confirmed in broader use.

In neurology, Novartis already has experience in multiple sclerosis and other disorders, but Alzheimers represents one of the largest and most challenging indications in the central nervous system category. The launch of Kisunla therefore has an outsized influence on how investors view the companys neurology franchise and its ability to compete with other global pharmaceutical companies in disease-modifying therapies for neurodegenerative conditions. Success in this field could support higher medium-term growth expectations, while setbacks could reinforce perceptions of risk inherent in high-cost late-stage research.

Beyond individual products, Novartis continues to emphasize productivity measures, targeting efficiency gains across manufacturing and administrative functions. In the 2025 results commentary, the company pointed to cost savings initiatives that helped to support the roughly 2 percentage point improvement in core operating margin seen between 2024 and 2025. For investors, improvements in margin are critical because they enhance earnings resilience even if top-line growth remains in the mid single-digit range.

Regulatory and pricing environment remains a key variable

The launch and commercialization of Kisunla occur against the backdrop of evolving pricing and reimbursement frameworks in major markets, particularly the United States and Europe. In the US, legislative measures affecting pricing and potential negotiated rates under public programs create uncertainty for long-duration therapies. Novartis has acknowledged in its risk disclosures that pricing pressure and access hurdles can influence realized net prices and volumes across the portfolio, including for high-profile innovative medicines.

In Europe, healthcare systems are also seeking value-based arrangements and evidence of cost-effectiveness, which can affect the pace of uptake and the breadth of reimbursement of new medicines. For Alzheimers treatments, payers will likely monitor real-world outcomes data carefully, assessing whether clinical benefits translate into measurable reductions in long-term care needs. These dynamics mean that while blockbuster forecasts capture attention, the actual financial trajectory of Kisunla and other pipeline assets will depend on a combination of clinical performance, regulatory decisions, and reimbursement negotiations.

Novartis addresses these uncertainties by investing in real-world evidence programs and health economics studies to support the value proposition of its medicines. This is particularly important in chronic and progressive conditions where the benefits of treatment accumulate over years. For investors analyzing Novartis stock, the quality and quantity of such evidence may influence assumptions about sustainable pricing levels and peak sales potential for key products.

Balance sheet and cash generation support flexibility

The 2025 financial statements for Novartis, as summarized in the companys annual report, indicate that the group generated operating cash flow in the region of $18 billion in 2025, compared with about $17 billion in 2024. This incremental increase, though smaller than the growth in core net income, underscores the conversion of earnings into cash. Capital expenditure remained in the mid single-digit billions of dollars, leaving ample free cash flow to fund dividends, share repurchases, and strategic investments.

Net debt levels remained manageable relative to earnings, with Novartis describing its balance sheet as strong and investment-grade in its investor communications. The combination of significant free cash flow and a solid balance sheet provides flexibility for further pipeline-focused deals or targeted acquisitions that complement internal research and development capabilities. For example, bolt-on acquisitions of small to mid-size biotech companies with promising assets in oncology, immunology, or neurology can be absorbed without fundamentally altering the leverage profile.

For investors, this financial flexibility introduces an additional layer of optionality on top of the organic growth profile. If internal pipeline programs underperform, external innovation can be brought in, while in periods of strong internal success, excess cash can be returned to shareholders. Assessing the discipline with which Novartis deploys this flexibility is therefore part of the longer-term investment analysis for the stock.

Novartis products anchor long-term growth

Novartis continues to rely on a diversified portfolio of innovative medicines across therapeutic areas. Product lines such as Entresto and Cosentyx, alongside oncology agents and emerging therapies like Kisunla, form the backbone of the groups growth strategy. According to its 2025 annual results documents, management expects that a core group of around ten to fifteen major brands will drive the majority of incremental sales over the medium term.

In addition to these key drugs, Novartis maintains a pipeline of earlier-stage assets in immunology, oncology, cardiovascular, and neuroscience. The company highlights in its research and development presentations that it has dozens of ongoing Phase II and Phase III studies aimed at securing future approvals. While individual trial outcomes are uncertain, the breadth of the pipeline is designed to balance risk across multiple mechanisms of action and disease areas. For investors, this breadth contributes to the probability that at least some candidates will translate into future blockbusters.

From the perspective of patients and healthcare systems, the focus on high unmet medical needs and disease-modifying therapies means that successful products can create significant clinical value. For Novartis, turning this clinical value into financial returns depends on maintaining competitive differentiation and securing favorable access conditions. The interplay between scientific innovation, pricing constraints, and competition will thus remain central to how Novartis stock is valued over time.

Novartis stock and valuation context

Novartis stock is included in major indices such as the Swiss Market Index, reflecting its role as one of the largest healthcare constituents in the Swiss equity market. The companys market capitalization stood in the range of CHF 180 billion to CHF 190 billion at various points in 2025 and early 2026, based on prevailing share prices and public data compiled on market portals. That places Novartis among the largest pharmaceutical groups globally by equity value.

At a share price in the low triple digits in Swiss francs on SIX Swiss Exchange in early 2026, Novartis stock traded near the upper part of its twelve-month range, according to data visible on Swiss exchange-focused quote services. The stock price was supported by the combination of consistent dividend growth, margin expansion, and expectations for pipeline contributions. However, as with other large pharmaceutical names, valuation also reflects investor views on regulatory risk, patent expiries, and competition from generics and biosimilars.

For portfolio managers and individual investors, Novartis stock tends to be analyzed both relative to global pharma peers and within broader defensive equity allocations. The stocks behavior in periods of market volatility often reflects its role as a large-cap healthcare holding with relatively stable cash flows, although company-specific news such as clinical trial readouts or regulatory decisions can still lead to meaningful short-term price reactions.

Novartis key immunology brands

Among the various medicines that support the Novartis growth profile, Cosentyx illustrates the companys presence in immunology. As noted, sales of approximately $6.0 billion in 2025 underscore its position as a major treatment option for psoriasis and certain arthritic conditions. The continued expansion into additional indications and geographies remains a focus in the companys life-cycle management strategy for the drug.

Beyond Cosentyx, Novartis has other immunology and inflammation medicines in development, some of which target rarer diseases with high unmet need. Successful launches in such indications can generate attractive pricing power if payers recognize significant clinical benefit. However, the relatively small patient numbers involved may limit the absolute revenue contribution compared with mass-market cardiovascular or neurology drugs. In aggregate, these immunology products contribute to diversifying the companys earnings mix beyond a narrow set of blockbusters.

Novartis stock trading snapshot

On the primary listing on SIX Swiss Exchange, Novartis shares most recently changed hands at around CHF 100 per share, based on quote information available from Swiss market data portals for a trading day in July 2026. That level is within sight of a twelve-month high in the low CHF 100s and well above the twelve-month low in the low CHF 80s, suggesting that the stock has delivered positive total return over the past year when dividends are included.

At this approximate price level, and using the 2025 core net income figure of about $16 billion translated into Swiss francs for rough comparison, investors may view Novartis as trading on a valuation that reflects its status as a mature, cash-generative large-cap with renewed growth drivers from products like Kisunla. The market will continue to adjust this valuation as new clinical data, regulatory decisions, and competitive developments emerge for key medicines in the portfolio.